Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals. We also guarantee that you cannot find matched quality at such competitive and economic pricing.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free.
Our insightful and holistic reports have helped corporate,academia and researchers to take their research forward. Like us on Facebook to stay updated with the latest published SWOT & PESTLE Report.

AstraZeneca SWOT & PESTLE Analysis

ID : 52398853| May 2018| 17 pages

COMPANY PROFILE -AstraZeneca

Business Sector :Biopharmaceutical and Pharmaceutical

Operating Geography :United Kingdom, Global

About AstraZeneca :

AstraZeneca is an Anglo-Swedish global pharmaceutical and biopharmaceutical company with headquarter in Cambridge, United Kingdom. The business is driven and led by science, technology and innovation, providing medicines used by millions of patients worldwide. The company was founded in 1999 by the merger of Swedish Astra AB and the British Zeneca group and has a market cap of $ 90.7 Billion as on April 18, 2018. The product portfolio on the group consists of medicines for curing diseases such as Cancer, Cardio vascular, Respiratory, Neuroscience, Oncology, Infection and Vaccines.
AstraZeneca’s mission as per their website is to “turn ideas into life-changing medicines that improve patients’ lives and benefit society.”

AstraZeneca Revenue :


$ 22.46 Billion (year ending 31 December 2017)
$ 23.00 Billion (year ending 31 December 2016)

Competitive Analysis of AstraZeneca

SWOT
PESTLE
The SWOT analysis for AstraZeneca is presented below:
Strengths
Weaknesses
1. Ranked first in innovation index.
2. High percentage of R&D Expenditure amongst the industry leaders.
3. Strong financial performance.
1. Bad public relations image and other controversies
2. High failure rate for drug leads to high operational losses.
3. Lack of inspirational leadership and other top management concerns.
Opportunities
Threats
1. Vast growth opportunities in the emerging markets that can be future drivers for growth.1. Acquisition by financially bigger and wealthier companies.
2. Loss of revenue because of generics.
3. High drug development cost.
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
Great quality, Affordable pricing.
Safe and secure payments

Detailed SWOT Analysis of AstraZeneca

 

Strength

1. Ranked first in the Innovation Index: In 2018 AstraZeneca topped the Pharmaceutical Innovation Index released by IDEA pharma for the first time leading behind industry leaders such as Johnson&Johnson, Pfizer, Abbot, Novartis, Bayer, Sanofi, Glaxo Smith Kline and many others, AstraZeneca topped the ranking even though they were ranked on the 15th spot in 2017, this comes on the back of some key strategic decisions taken by the management at AstraZeneca that helped to pipeline the positive data and ideas and stem the company’s downward trend because of the loss of several exclusive products between the year 2011 and 2017. AstraZeneca was considerably behind in developing cancer immunotherapy drugs which the market leaders such as Merck, Roche and Bristol-Myers were also competing for but the successful test trials by AstraZeneca could give it a major advantage. The main reason that AstraZeneca topped the Pharmaceutical Innovation Index in 2018 from the 15th position was the launch of five new significant medicines in 2017 primarily across their therapy areas which are no mean feat for a company in the industry.

2. High percentage of R&D Expenditure amongst the industry leaders: In absolute spending on R&D AstraZeneca ranks at the 6th spot overall in the pharmaceutical industry in Financial Year 2017 despite being much smaller in size in terms of revenue than some of its competitors, it outperforms Bristol-Myers Squibb, Sanofi and GlaxoSmithKline all of which have a higher revenue than AstraZeneca, this comes on the back of a decline in revenue in 2017 by more than 2% than that in 2016, but the company showed positive results in the Q4 of FY 2017 where its revenue grew by 3% than that in Q4 of FY 2016. On an average the top ten Pharmaceutical companies by their market capitalization shelled out 17% of their revenues on R&D, whereas AstraZeneca proved to set the benchmark in this aspect as they spent just more than 25% of their revenues, this comes at a time when the total spending on R&D by the top 10 companies combined stood at $ 70 Billion in 2017 which has been stagnant for the past 5 to 6 years as the total spending of $ 70 Billion was spent in 2011 and 2012.

3. Strong Financial performance: AstraZeneca has suffered a big setback since 2012 when their patents on some key pharmaceutical products expired and the exclusivity of those products was lost because of which the company saw a decline of 15% in revenue in 2012 and the sales reduced to half than the year before. The company steadily recovered from this loss through the 6 years and in 2018 AstraZeneca announced that they have returned to sales growth in the Financial Year 2017 Q4; that was largely driven by newly developed cancer treatments, oncology pills (new oncology treatments registered for 98% growth), treatment of lung diseases and a sales growth in emerging market of 6%, China which saw a sales growth of 15% in 2017 and 33% in Q4 of FY17 supported by launch of new medicines. And with the optimistic results in the Q4 FY 2017, the company wants to reach target revenue of $ 45 Billion by the year 2023.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

This section is available only in the 'Complete Report' on purchase.

Threat

This section is available only in the 'Complete Report' on purchase.

SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
Great quality, Affordable pricing.
Safe and secure payments

Check out analysis of other relevant companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
References used in AstraZeneca Analysis Report

1. https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20announcement%20.pdf

2. https://www.investorschronicle.co.uk/tips-ideas/2018/02/02/astrazeneca-returns-to-sales-growth/

3. https://www.pharmamanufacturing.com/industrynews/2018/astrazeneca-partners-with-tech-giants-to-reach-china-market/

Copyrights and Disclaimer

AstraZeneca SWOT and PESTLE analysis has been conducted by Deepankar Pandey and reviewed by senior analysts from Barakaat Consulting.

Copyright of AstraZeneca SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

AstraZeneca SWOT & PESTLE Analysis
Price : USD 12.53